Literature DB >> 10408848

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

N Harbeck1, P Dettmar, C Thomssen, U Berger, K Ulm, R Kates, H Höfler, F Jänicke, H Graeff, M Schmitt.   

Abstract

Factors reflecting two major aspects of tumour biology, invasion (urokinase-type plasminogen activator (uPA), plasminogen activator inhibiter (PAI-1), cathepsin D) and proliferation (S-phase fraction (SPF), Ki-67, p53, HER-2/neu), were assessed in 125 node-negative breast cancer patients without adjuvant systemic therapy. Median follow-up time was 76 months. Antigen levels of uPA, PAI-1 and cathepsin D were immunoenzymatically determined in tumour tissue extracts. SPF and ploidy were determined flow-cytometrically, Ki"'-67, p53, and HER-2/neu immunohistochemically in adjacent paraffin sections. Their prognostic impact on disease-free (DFS) and overall survival (OS) was compared to that of traditional factors (tumour size, grading, hormone receptor status). Univariate analysis determined PAI-1 (P < 0.001), uPA (P = 0.008), cathepsin D (P = 0.004) and SPF (P = 0.023) as significant for DFS. All other factors failed to be of significant prognostic value. In a Cox model, only PAI-1 was significant for DFS (P < 0.001, relative risk (RR) 6.2). In CART analysis for DFS, the combination of PAI-1 and uPA gave the best risk group discrimination. For OS, PAI-1, cathepsin D, tumour size and ploidy were statistically significant in univariate, but PAI-1 was the only independently significant factor in Cox analysis (P < 0.001, RR 8.9). In particular, this analysis shows that PAI-1 is still a strong and independent prognostic factor in node-negative breast cancer after extended 6-year median follow-up.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408848      PMCID: PMC2362313          DOI: 10.1038/sj.bjc.6690373

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Cathepsin D in breast cancer: a tissue marker associated with metastasis.

Authors:  H Rochefort
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 2.  Breast cancer (3).

Authors:  J R Harris; M E Lippman; U Veronesi; W Willett
Journal:  N Engl J Med       Date:  1992-08-13       Impact factor: 91.245

Review 3.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer.

Authors:  W L McGuire; G M Clark
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

4.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

Authors:  F Jänicke; L Pache; M Schmitt; K Ulm; C Thomssen; A Prechtl; H Graeff
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

Review 5.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Authors:  F Jänicke; M Schmitt; L Pache; K Ulm; N Harbeck; H Höfler; H Graeff
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.

Authors:  C R Wenger; S Beardslee; M A Owens; G Pounds; T Oldaker; P Vendely; M R Pandian; D Harrington; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

8.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Authors:  J Grøndahl-Hansen; I J Christensen; C Rosenquist; N Brünner; H T Mouridsen; K Danø; M Blichert-Toft
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

9.  Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry.

Authors:  G Gasparini; P Boracchi; P Verderio; P Bevilacqua
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

10.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Authors:  C Bouchet; F Spyratos; P M Martin; K Hacène; A Gentile; J Oglobine
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  15 in total

1.  Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors.

Authors:  Fatima Cardoso
Journal:  Breast Care (Basel)       Date:  2008-12-02       Impact factor: 2.860

2.  Node-Negative Breast Cancer: Which Patients Should Be Treated?

Authors:  Marcus Schmidt
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

3.  A functional and regulatory network associated with PIP expression in human breast cancer.

Authors:  Marie-Anne Debily; Sandrine El Marhomy; Virginie Boulanger; Eric Eveno; Régine Mariage-Samson; Alessandra Camarca; Charles Auffray; Dominique Piatier-Tonneau; Sandrine Imbeaud
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

4.  Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

Authors:  M Knauer; F Cardoso; J Wesseling; P L Bedard; S C Linn; E J T Rutgers; L J van 't Veer
Journal:  Br J Cancer       Date:  2010-11-16       Impact factor: 7.640

Review 5.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

6.  Prognostic significance of deregulated dicer expression in breast cancer.

Authors:  Emer Caffrey; Helen Ingoldsby; Deirdre Wall; Mark Webber; Kate Dinneen; Laura S Murillo; Celine Inderhaug; John Newell; Sanjeev Gupta; Grace Callagy
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

7.  Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.

Authors:  Marcus Schmidt; Barbara Lewark; Nikolai Kohlschmidt; Christiane Glawatz; Erik Steiner; Berno Tanner; Henryk Pilch; Wolfgang Weikel; Heinz Kölbl; Hans-Anton Lehr
Journal:  Breast Cancer Res       Date:  2005-01-26       Impact factor: 6.466

8.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

Authors:  E de Azambuja; F Cardoso; G de Castro; M Colozza; M S Mano; V Durbecq; C Sotiriou; D Larsimont; M J Piccart-Gebhart; M Paesmans
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

9.  Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.

Authors:  Wenrui Hao; Avner Friedman
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

10.  Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.

Authors:  Maja Lampelj; Darja Arko; Nina Cas-Sikosek; Rajko Kavalar; Maja Ravnik; Barbara Jezersek-Novakovic; Sarah Dobnik; Nina Fokter Dovnik; Iztok Takac
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.